Certa Plans Pivotal Scleroderma Trial As GPCR Antagonist Hits Phase II Bullseye
Australian Firm Has High Hopes
Certa’s lead candidate has shown promise in a mid-stage trial for the rare but debilitating skin disorder, triggering pivotal development plans to address the high unmet need.
